Aequus Pharmaceuticals Provides Additional Shareholder Meeting Details
VANCOUVER, November 12, 2025 — Leads & Copy — Aequus Pharmaceuticals Inc. (TSX-V: AQS) has released additional information regarding its upcoming annual general and special meeting of shareholders at the request of the Ontario Securities Commission.
The meeting is scheduled for November 21, 2025. The company is providing supplemental information to the management information circular dated October 20, 2025, with the updated details not changing anything else in the original version.
Concerning the potential consolidation of the company’s common shares, Aequus clarified that the Share Consolidation will not proceed if a material change occurs that increases the market price or value of the Common Shares or if there is a material fact not publicly disclosed that would reasonably be expected to increase the market price or value of the Common Shares if disclosed. This clarification supplements the circular’s disclosure related to whether this may be considered a “business combination”.
The company also clarified that if it is not listed on an organized trading facility when the Share Consolidation is implemented, the payout value for fractional Common Shares will be the fair value as determined in good faith by the board of directors. For illustrative purposes, the estimated payout value would be $[●] for each whole Common Share if the Share Consolidation were implemented as of Nov. 12, 2025.
The company is also supplementing information about Marc Lustig, a director nominee for the Meeting, who is subject to a cease trade order issued by the British Columbia Securities Commission on July 21, 2025. The order resulted from Mr. Lustig not filing insider reports for changes to his beneficial ownership of certain reporting issuers, including Aequus, within the prescribed time, as required by National Instrument 55-104 – Insider Reporting Requirements and Exemptions and National Instrument 55-102 – System for Electronic Disclosure by Insiders (SEDI). This order prohibits Mr. Lustig from trading securities of any reporting issuer, including Aequus, while the order is in effect.
Mr. Lustig was the Chief Executive Officer of PharmaCielo Ltd. when the Ontario Securities Commission issued a failure to file cease trade order (FFCTO) against the company on August 6, 2025. The FFCTO was issued due to PharmaCielo’s delay in filing its audited annual consolidated financial statements for the year ended March 31, 2025, the related management’s discussion and analysis and certifications. PharmaCielo subsequently filed the Annual Filings on October 24, 2025, and the FFCTO was revoked on October 27, 2025.
Aequus Pharmaceuticals Inc. (TSX-V: AQS) is a specialty pharmaceutical company focused on commercializing value-added products in specialty therapeutic areas in the Canadian market.
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906
Source: Aequus Pharmaceuticals Inc.
Share this story:
